LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels

Peter M.A. Calverley (Liverpool, United Kingdom), Peter Calverley, Christoph Hallmann, Norbert Metzdorf, Lars Grnke, Achim Mueller, David Halpin

Source: International Congress 2015 – Emerging strategies for airway disease treatments
Session: Emerging strategies for airway disease treatments
Session type: Thematic Poster Session
Number: 4362
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Peter M.A. Calverley (Liverpool, United Kingdom), Peter Calverley, Christoph Hallmann, Norbert Metzdorf, Lars Grnke, Achim Mueller, David Halpin. LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Eur Respir J 2015; 46: Suppl. 59, 4362

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016


LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015


Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


LATE-BREAKING ABSTRACT: Validation of the DECAF score to predict hospital mortality in exacerbations of COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015

LATE-BREAKING ABSTRACT: Predictive factors of frequent exacerbations in mild grade COPD patients
Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care
Year: 2016


QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013



Relationship of blood eosinophil count to exacerbations in COPD
Source: International Congress 2016 – Airway response to infection
Year: 2016


LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene
Source: International Congress 2014 – COPD exacerbations
Year: 2014


LATE-BREAKING ABSTRACT: Eosinophilic inflammation in COPD: During clinical stability and exacerbations. The AERIS study
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015


LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013


LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016

LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016

Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015

QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014


LATE-BREAKING ABSTRACT: Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016


COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014

LATE-BREAKING ABSTRACT: Can patients with COPD assimilate disease specific information at a time of being acutely unwell due to an exacerbation of their disease?
Source: International Congress 2016 – Best abstracts on innovative outcomes and novel interventions in respiratory physiotherapy
Year: 2016